

The value of vaccination

Builds NHS resilience and helps cut waiting lists¹

Vaccination has reduced the impact of RSV on hospitals. In 2024/25 there were:



50% fewer newborn RSV intensive care admissions
30% fewer RSV admissions among 75–79s.^{2,3}

Flu vaccination prevented around 100,000 hospital admissions in both 2024/25 and 2025/26. Higher uptake could ease pressure on primary care and hospitals.^{4,5}



Vaccination is a cornerstone of a resilient and equitable health system.⁶



Vaccination programmes offer unparalleled value for money.⁷



The NHS saves an estimated £400m annually from some vaccination programmes.⁷

One of the most powerful and effective public health interventions⁶



Pre-school vaccinations are estimated to prevent **4,960 deaths** and **228,447 hospitalisations** each year in England.⁸


HPV vaccination reduced recorded cervical cancer deaths to zero in women aged 20–24 between 2020 and 2024.^{9,10}



Preventing flu or pneumonia **cuts heart attack and stroke risk by 30–60%** for people with pre-existing conditions.¹¹



1m+ people die from antimicrobial resistance (AMR) globally each year. **Vaccines are crucial in tackling it.**¹²




Immunisation has helped **cut global infant deaths by 40%** over the last 50 years.¹³

Supports productivity and economic growth



Vaccination is both a **health imperative** and a **powerful economic strategy**.^{14,15}

Adult respiratory vaccination programmes **deliver socio-economic benefits that far exceed their costs**, with an up to **19.3x** return on investment.¹⁶



School flu outbreaks cause **3.8 days off school for an ill child** and **3.7 days off work** for carers. Vaccination helps keep children in school.^{6,17}

Meningitis can cause permanent, life-changing after-effects. Vaccination can prevent some types.^{18,19}



COVID-19's economic burden remains substantial, with **lost productivity costs 7x higher** than NHS costs.²⁰

¹ Neri M, et al., 'Vaccine-Preventable Hospitalisations from Seasonal Respiratory Diseases: What Is Their True Value?', *Vaccines*, Vol 11, 5, 945, 2023, available at <https://pubmed.ncbi.nlm.nih.gov/37243948/>. ² UK Health Security Agency, 'Newborn ICU admissions drop 50% in first full year of RSV maternal vaccine programme', accessed September 2026, available at <https://www.gov.uk/government/news/rsv-maternal-vaccine-cuts-baby-hospital-admissions-by-up-to-50>. ³ Mersich A, et al., 'Early impact of RSV vaccination in older adults in England', *The Lancet*, Volume 408, Issue 10488, 2025, Pages 1159–1160, [https://doi.org/10.1016/S0140-6736\(25\)00348-0](https://doi.org/10.1016/S0140-6736(25)00348-0). ⁴ UK Health Security Agency, 'Flu vaccine prevented around 100,000 hospital admissions', accessed July 2026, available at <https://www.gov.uk/government/news/flu-vaccine-prevented-around-100000-hospital-admissions>. ⁵ UK Health Security Agency, 'Influenza in the UK, annual epidemiological report: winter 2025 to 2026', accessed July 2026, available at <https://www.gov.uk/government/statistics/influenza-in-the-uk-annual-epidemiological-report-winter-2025-to-2026>. ⁶ Department of Health and Social Care, Department of Education, Medicines and Healthcare Products Regulatory Agency, NHS England and UK Health Security Agency, 'Written Evidence (CVX0028) to House of Lords Childhood Vaccination Committee', accessed July 2026, available at <https://committees.parliament.uk/writtenevidence/166194/pdf>. ⁷ UK Health Security Agency, 'UKHSA Advisory Board: Immunisation Schedule, May 2024', accessed July 2026, available at <https://www.gov.uk/government/publications/ukhsa-advisory-board-agenda>. ⁸ UK Health Security Agency, 'Estimated annual deaths and hospitalisations prevented by routine childhood immunisation - England, 2026', accessed July 2026, available at <https://www.gov.uk/government/publications/routine-childhood-immunisation-deaths-and-hospitalisations-prevented-estimated-annual-deaths-and-hospitalisations-prevented-by-routine-childhood-immunisation-england-2026>. ⁹ Sasieni P and Falcaro M, 'Cervical cancer mortality trends following HPV vaccination in England, 2001–24: an analysis of population-based mortality data', *The Lancet*, accessed July 2026, available at [https://doi.org/10.1016/S0140-6736\(26\)00938-3](https://doi.org/10.1016/S0140-6736(26)00938-3). ¹⁰ Mohale S, 'HPV jab: cervical cancer deaths fall to zero in vaccinated young women, research shows', accessed August 2026, available at <https://www.bbc.com/content/3/3/2026-08-04>. ¹¹ IFPMA and the Global Coalition on Aging, 'Adult Immunization for Healthy Workforces and Healthy Economies in an Aging World: Infographic 2026', accessed July 2026, available at <https://www.ifpma.org/resources/adult-immunization-for-healthy-workforces-and-healthy-economies-in-an-aging-world>. ¹² GBD 2021 Antimicrobial Resistance Collaborators, 'Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050', *The Lancet*, Vol 404, 10459, 1199–1226, 28 Sep 2024, available at [https://www.thelancet.com/journals/lanct/article/PIIS0140-6736\(24\)00887-1/fulltext](https://www.thelancet.com/journals/lanct/article/PIIS0140-6736(24)00887-1/fulltext). ¹³ Unicef, 'Facts about vaccines: Why vaccines matter for children 2025', accessed July 2026, available at <https://www.unicef.org/stories/why-vaccines-matter-children>. ¹⁴ The Vaccine Alliance, 'The economic impact of vaccination', accessed July 2026, available at <https://www.vaccinealliance.org/press/press-room>. ¹⁵ UK Health Security Agency, 'Immunisation Equity Strategy: Commitments for 2025 to 2030', accessed July 2026, available at <https://www.gov.uk/government/publications/ukhsa-immunisation-equity-strategy-commitments-for-2025-to-2030>. ¹⁶ Harrison C, et al (2025), 'The broader socio-economic value of adult respiratory disease vaccinations in the UK – results from a benefit cost analysis', *Expert Review of Vaccines*, 24(1), 644–655, available at <https://doi.org/10.1080/14767694.2025.2336923>. ¹⁷ Thornton D, et al, 'Social and economic impacts of school influenza outbreaks in England: survey of caregivers', *J Sch Health*, 2017;87(5):209–218, available at <https://pubmed.ncbi.nlm.nih.gov/28147469/>. ¹⁸ Meningitis Now, 'After-effects of meningitis', accessed July 2026, available at <https://www.meningitisnow.org/after-effects-of-meningitis>. ¹⁹ Meningitis Now, 'What meningitis vaccines are available in the UK?', accessed July 2026, available at <https://www.meningitisnow.org/what-meningitis-vaccines-are-available-in-the-uk/>. ²⁰ El Bahawi, H, et al, 'The broader economic benefits of COVID-19 vaccination (2025) – Contract Research', accessed July 2026, available from <https://www.ohre.org/publications/the-broader-economic-benefits-of-covid-19-vaccination>.